Czech Academy institute building 3D tissue models and nanofiber scaffolds for drug testing, toxicology screening, and regenerative medicine.
The Institute of Experimental Medicine of the Czech Academy of Sciences (IEM CAS) develops advanced 3D tissue models, nanofiber-based scaffolds, and drug delivery systems for regenerative medicine and toxicology screening. Their core capability lies in building organotypic cell culture platforms — from iPSC-seeded bone/cartilage scaffolds to brain-relevant models for studying nanoparticle toxicity. They bridge materials science and biomedicine, creating tools that let researchers test drugs, assess toxicity, and model diseases like osteoporosis and Alzheimer's in lab settings that mimic real tissue. Their work feeds directly into personalized medicine and preclinical drug development pipelines.
Core theme across iP-OSTEO (osteochondral scaffolds), ActiTOX (organotypic 3D models), and ASTROTECH (advanced biomaterials), covering electrospinning, bioreactors, and biomimetic scaffold design.
TUBE studied transport-derived ultrafine particle effects on the brain, while ActiTOX built organotypic screening models for nanoparticle ADME and toxicity assessment.
iP-OSTEO — their only coordinated project — developed iPSC-seeded nanofibrous scaffolds targeting osteoporosis and osteoarthritis, combining stem cell biology with materials engineering.
Contributed to HBM4EU as a third party, working on exposure biomarkers, endocrine disruptors, and chemical mixture reference values across European cohorts.
TUBE (brain effects of traffic nanoparticles) and ASTROTECH (biomaterials for studying astrocyte function, neurostimulation) signal growing investment in neurological applications.
Their earliest H2020 involvement (2017) centered on population-level chemical exposure monitoring through HBM4EU, alongside iPSC-based musculoskeletal tissue engineering in iP-OSTEO. From 2019 onward, the focus shifted decisively toward nanotoxicology and neuroscience — studying how nanoparticles cross biological barriers, building brain-relevant 3D models, and developing biomaterials for neurostimulation. The through-line is 3D cell culture and scaffold technology, but the application domain has migrated from bone/cartilage toward brain and neurological systems.
IEM is converging its scaffold/3D culture expertise with neuroscience applications, positioning itself as a go-to lab for in vitro brain tissue models and nanoparticle neurotoxicity testing.
IEM primarily joins consortia as a specialist partner, contributing specific technical capabilities (3D models, nanofiber fabrication, toxicology assays) rather than leading large projects. They coordinated one MSCA-RISE project (iP-OSTEO) focused on staff exchange, suggesting comfort with network-building but not large-scale project management. With 151 unique partners across 32 countries from just 5 projects, they operate within very large consortia and have broad international exposure — typical of an institute that provides niche expertise to diverse teams.
Despite only 5 projects, IEM has connected with 151 partners across 32 countries — a remarkably wide network driven by participation in large-scale initiatives like HBM4EU. Their reach spans well beyond Central Europe into Western European research hubs and beyond.
IEM sits at the intersection of advanced materials fabrication (electrospinning, nanofibers, 3D printing) and biological testing — they don't just make scaffolds, they build functional tissue models and run toxicology screens on them. This combination is rare: most biomaterials labs hand off testing to others, while most toxicology labs use commercial kits. For a consortium needing someone who can both fabricate a custom 3D tissue model AND validate drug or nanoparticle behavior in it, IEM is a strong single-source partner from the Czech Academy of Sciences system.
